1 min read
Add as a preferred source on GoogleEyePoint Expects COMO, CAPRI Phase 3 Data in Early Q4 2027
The company is focusing its Phase 3 program on DURAVYU for diabetic macular edema.
EyePoint expects top-line data from its COMO and CAPRI studies early in the fourth quarter of 2027. The studies are part of the company’s Phase 3 program in diabetic macular edema (DME), which focuses on DURAVYU.
The expected data window is early Q4 2027.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.